William Blair Has Positive Forecast for ANRO FY2024 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for Alto Neuroscience in a research report issued on Wednesday, November 13th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($2.65) for the year, up from their prior estimate of ($2.73). William Blair has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.60) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($3.06) EPS.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05.

Several other research firms have also commented on ANRO. Stifel Nicolaus dropped their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Robert W. Baird lowered their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. RODMAN&RENSHAW downgraded Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Finally, Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Alto Neuroscience Stock Down 1.7 %

Shares of NYSE ANRO opened at $4.52 on Monday. The company has a current ratio of 13.10, a quick ratio of 19.85 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 12 month low of $3.61 and a 12 month high of $24.00. The company has a 50-day simple moving average of $9.69 and a 200-day simple moving average of $11.30.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. purchased a new position in shares of Alto Neuroscience in the first quarter worth approximately $8,233,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Alto Neuroscience in the first quarter worth $9,788,000. AWM Investment Company Inc. purchased a new stake in shares of Alto Neuroscience during the first quarter worth $4,592,000. Zimmer Partners LP purchased a new position in Alto Neuroscience in the first quarter valued at about $1,151,000. Finally, Artal Group S.A. purchased a new stake in shares of Alto Neuroscience during the 1st quarter worth about $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.